Mao H, et al. - Via a cross-sectional survey, the prevalence and risk factors for fatigue were determined among postmenopausal women with stage 0 to III breast cancer (BC) receiving adjuvant aromatase inhibitor (AI) therapy at the outpatient breast oncology clinic of a large university hospital. Among AI users, moderate to severe fatigue complaints were higher than 50%. Significant relation between fatigue and younger age, higher education level, higher body mass index (BMI), pain severity and insomnia was observed. Moderate to severe fatigue was significantly more likely to be seen in women younger than 55 years and in women with college or more education, vs women older than 65 years or women with high school or less education. Increasing BMI was found to be significantly related to increased risk of experiencing moderate to severe fatigue.